Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Antifungal agents for invasive candidiasis in non-neutropenic critically ill adults: What do the guidelines recommend?

Wang Y, McGuire TM, Hollingworth SA, Dong Y, Van Driel ML.

Int J Infect Dis. 2019 Oct 19;89:137-145. doi: 10.1016/j.ijid.2019.10.016. [Epub ahead of print]

2.

Strategies to counter antipsychotic-associated weight gain in patients with schizophrenia.

Marteene W, Winckel K, Hollingworth S, Kisely S, Gallagher E, Hahn M, Ebdrup BH, Firth J, Siskind D.

Expert Opin Drug Saf. 2019 Oct 11:1-12. doi: 10.1080/14740338.2019.1674809. [Epub ahead of print]

PMID:
31564170
3.

Evaluation of the Influence of Raw Almonds on Appetite Control: Satiation, Satiety, Hedonics and Consumer Perceptions.

Hollingworth S, Dalton M, Blundell JE, Finlayson G.

Nutrients. 2019 Aug 30;11(9). pii: E2030. doi: 10.3390/nu11092030.

4.

Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.

Olsen A, Lawton B, Dwyer R, Taing MW, Chun KLJ, Hollingworth S, Nielsen S.

Int J Drug Policy. 2019 Jul;69:46-52. doi: 10.1016/j.drugpo.2019.03.020. Epub 2019 May 9.

PMID:
31078908
5.

Response to Comment on Johnson et al. Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life. Diabetes Care 2019;42:69-76.

Johnson SR, Carter HE, Leo P, Hollingworth SA, Davis EA, Jones TW, Conwell LS, Harris M, Brown MA, Graves N, Duncan EL.

Diabetes Care. 2019 May;42(5):e79-e80. doi: 10.2337/dci19-0010. No abstract available.

PMID:
31010948
6.

Longitudinal impact of the Women's Health Initiative study on hormone therapy use in Australia.

Natari RB, McGuire TM, Baker PJ, Clavarino AM, Dingle KD, Hollingworth SA.

Climacteric. 2019 Oct;22(5):489-497. doi: 10.1080/13697137.2019.1593357. Epub 2019 Apr 23.

PMID:
31010331
7.

How prepared are pharmacists to provide over-the-counter naloxone? The role of previous education and new training opportunities.

Lai Joyce Chun K, Olsen A, Taing MW, Clavarino A, Hollingworth S, Dwyer R, Middleton M, Nielsen S.

Res Social Adm Pharm. 2019 Aug;15(8):1014-1020. doi: 10.1016/j.sapharm.2019.03.003. Epub 2019 Mar 22.

PMID:
30926251
8.

Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life.

Johnson SR, Carter HE, Leo P, Hollingworth SA, Davis EA, Jones TW, Conwell LS, Harris M, Brown MA, Graves N, Duncan EL.

Diabetes Care. 2019 Jan;42(1):69-76. doi: 10.2337/dc18-0261. Epub 2018 Dec 6.

PMID:
30523035
9.

Medicine use during acute and chronic postinjury periods in whiplash-injured individuals.

Ritchie C, Hollingworth SA, Warren J, Sterling M.

Pain. 2019 Apr;160(4):844-851. doi: 10.1097/j.pain.0000000000001460.

PMID:
30531309
10.

Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib.

McGrath AC, Sandhu G, Walpole E, McCaffrey E, Hollingworth SA.

Anticancer Drugs. 2018 Sep;29(8):786-790. doi: 10.1097/CAD.0000000000000640.

PMID:
30110016
11.

Does consumer medicines interest reflect medicines use? An observational study comparing medicines call center queries with medicines use.

Pache DM, Hollingworth SA, van Driel ML, McGuire TM.

Res Social Adm Pharm. 2019 Apr;15(4):440-447. doi: 10.1016/j.sapharm.2018.06.012. Epub 2018 Jun 18.

PMID:
29935855
12.

Prescription Opioid Fatalities: Examining Why the Healer Could be the Culprit.

Adewumi AD, Staatz CE, Hollingworth SA, Connor JP, Alati R.

Drug Saf. 2018 Nov;41(11):1023-1033. doi: 10.1007/s40264-018-0687-6. Review.

PMID:
29796831
13.

Correction to: Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014.

Hollingworth SA, Winckel K, Saiepour N, Wheeler AJ, Myles N, Siskind D.

Psychopharmacology (Berl). 2018 Jul;235(7):2193. doi: 10.1007/s00213-018-4909-5.

PMID:
29704218
14.

Clozapine-related neutropenia, myocarditis and cardiomyopathy adverse event reports in Australia 1993-2014.

Hollingworth SA, Winckel K, Saiepour N, Wheeler AJ, Myles N, Siskind D.

Psychopharmacology (Berl). 2018 Jul;235(7):1915-1921. doi: 10.1007/s00213-018-4881-0. Epub 2018 Mar 27. Erratum in: Psychopharmacology (Berl). 2018 Apr 23;:.

PMID:
29589067
15.

More needs to be spent on hepatitis C treatment, not less.

Clark PJ, Muranushi C, Hollingworth SA.

Intern Med J. 2018 Mar;48(3):364-366. doi: 10.1111/imj.13718. No abstract available.

PMID:
29512321
16.

Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose.

Adewumi AD, Hollingworth SA, Maravilla JC, Connor JP, Alati R.

CNS Drugs. 2018 Feb;32(2):101-116. doi: 10.1007/s40263-018-0499-3.

PMID:
29498021
17.

Patterns in use and costs of subsidising 5-aminosalicyclic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia.

Staatz CE, Martin NS, Kong DP, Hollingworth SA.

Dig Liver Dis. 2018 Mar;50(3):314-317. doi: 10.1016/j.dld.2017.12.016. Epub 2017 Dec 24. No abstract available.

PMID:
29311026
18.

Small Ca2+ releases enable hour-long high-frequency contractions in midshipman swimbladder muscle.

Nelson FE, Hollingworth S, Marx JO, Baylor SM, Rome LC.

J Gen Physiol. 2018 Jan 2;150(1):127-143. doi: 10.1085/jgp.201711760. Epub 2017 Dec 19.

19.

A perspective on Na and K channel inactivation.

Armstrong CM, Hollingworth S.

J Gen Physiol. 2018 Jan 2;150(1):7-18. doi: 10.1085/jgp.201711835. Epub 2017 Dec 12. Review.

20.

Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).

Siskind DJ, Russell AW, Gamble C, Winckel K, Mayfield K, Hollingworth S, Hickman I, Siskind V, Kisely S.

Diabetes Obes Metab. 2018 Apr;20(4):1050-1055. doi: 10.1111/dom.13167. Epub 2017 Dec 19.

PMID:
29194917
21.

Use of Healthcare Services by Patients with Non-Communicable Diseases in Nepal: A Qualitative Study with Healthcare Providers.

Khanal S, Veerman L, Nissen L, Hollingworth S.

J Clin Diagn Res. 2017 Jun;11(6):LC01-LC05. doi: 10.7860/JCDR/2017/25021.9970. Epub 2017 Jun 1.

22.

The bidirectional relationship between vasomotor symptoms and depression across the menopausal transition: a systematic review of longitudinal studies.

Natari RB, Clavarino AM, McGuire TM, Dingle KD, Hollingworth SA.

Menopause. 2018 Jan;25(1):109-120. doi: 10.1097/GME.0000000000000949. Review.

PMID:
28719420
23.

Opioid analgesic use in Australia and The Netherlands: a cross-country comparison.

Wagemaakers FN, Hollingworth SA, Kreijkamp-Kaspers S, Tee EHL, Leendertse AJ, van Driel ML.

Int J Clin Pharm. 2017 Aug;39(4):874-880. doi: 10.1007/s11096-017-0492-9. Epub 2017 Jun 12.

PMID:
28608330
24.

Using pharmacy management systems for research: survival outcomes for lenalidomide in multiple myeloma in the clinical setting.

Sharkey MM, McKavanagh D, Walpole E, Mollee P, Hollingworth SA.

Int J Clin Pharm. 2017 Aug;39(4):836-843. doi: 10.1007/s11096-017-0480-0. Epub 2017 Jun 1.

PMID:
28573439
25.

International trends in clozapine use: a study in 17 countries.

Bachmann CJ, Aagaard L, Bernardo M, Brandt L, Cartabia M, Clavenna A, Coma Fusté A, Furu K, Garuoliené K, Hoffmann F, Hollingworth S, Huybrechts KF, Kalverdijk LJ, Kawakami K, Kieler H, Kinoshita T, López SC, Machado-Alba JE, Machado-Duque ME, Mahesri M, Nishtala PS, Piovani D, Reutfors J, Saastamoinen LK, Sato I, Schuiling-Veninga CCM, Shyu YC, Siskind D, Skurtveit S, Verdoux H, Wang LJ, Zara Yahni C, Zoëga H, Taylor D.

Acta Psychiatr Scand. 2017 Jul;136(1):37-51. doi: 10.1111/acps.12742. Epub 2017 May 14.

PMID:
28502099
26.

Impact of a general practitioner-led integrated model of care on the cost of potentially preventable diabetes-related hospitalisations.

Hollingworth SA, Donald M, Zhang J, Vaikuntam BP, Russell A, Jackson C.

Prim Care Diabetes. 2017 Aug;11(4):344-347. doi: 10.1016/j.pcd.2017.03.009. Epub 2017 Apr 23.

PMID:
28442341
27.

Patterns in use and costs of conventional and biologic disease-modifying anti-rheumatic drugs in Australia.

Donges E, Staatz CE, Benham H, Kubler P, Hollingworth SA.

Clin Exp Rheumatol. 2017 Nov-Dec;35(6):907-912. Epub 2017 Apr 18.

PMID:
28421991
28.

Prescribing patterns of analgesics and other medicines by dental practitioners in Australia from 2001 to 2012.

Hollingworth SA, Chan R, Pham J, Shi S, Ford PJ.

Community Dent Oral Epidemiol. 2017 Aug;45(4):303-309. doi: 10.1111/cdoe.12291. Epub 2017 Mar 2.

PMID:
28251672
29.

The impact of clozapine on hospital use: a systematic review and meta-analysis.

Land R, Siskind D, McArdle P, Kisely S, Winckel K, Hollingworth SA.

Acta Psychiatr Scand. 2017 Apr;135(4):296-309. doi: 10.1111/acps.12700. Epub 2017 Feb 3. Review.

PMID:
28155220
30.

Triptan use in Australia 1997-2015: A pharmacoepidemiological study.

Eyre BLKD, Eadie MJ, van Driel ML, Ross-Lee L, Hollingworth SA.

Acta Neurol Scand. 2017 Aug;136(2):155-159. doi: 10.1111/ane.12727. Epub 2017 Jan 16.

PMID:
28093722
31.

Under-reporting of socio-economic status in randomized control trials of biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.

Chiu H, Hollingworth S, Van Driel M, Magin P, Benham H.

Rheumatology (Oxford). 2017 Apr 1;56(4):660-661. doi: 10.1093/rheumatology/kew460. No abstract available.

PMID:
28039418
32.

Ezetimibe: Use, costs, and adverse events in Australia.

Hollingworth SA, Ostino R, David MC, Martin JH, Tett SE.

Cardiovasc Ther. 2017 Feb;35(1):40-46. doi: 10.1111/1755-5922.12236.

PMID:
27860332
33.

Dopamine Agonists: Time Pattern of Adverse Effects Reporting in Australia.

Hollingworth SA, McGuire TM, Pache D, Eadie MJ.

Drugs Real World Outcomes. 2015 Sep;2(3):199-203.

34.

Case conference primary-secondary care planning at end of life can reduce the cost of hospitalisations.

Hollingworth S, Zhang J, Vaikuntam BP, Jackson C, Mitchell G.

BMC Palliat Care. 2016 Sep 23;15(1):84.

35.

Forecasting the quantity and cost of medicines to treat non-communicable diseases in low- and middle-income countries: Applying knowledge on medicine use from developed countries.

Khanal S, Veerman L, Nissen L, Hollingworth S.

Res Social Adm Pharm. 2017 Jan - Feb;13(1):257-258. doi: 10.1016/j.sapharm.2016.07.009. Epub 2016 Aug 10. No abstract available.

PMID:
27591096
36.

Off-label use of tumour necrosis factor-alpha inhibitors and anakinra at an Australian tertiary hospital.

Linger MW, van Driel ML, Hollingworth SA, Martin JH.

Intern Med J. 2016 Dec;46(12):1386-1391. doi: 10.1111/imj.13247.

PMID:
27572659
37.

Effectiveness of bevacizumab and cetuximab in metastatic colorectal cancer across selected public hospitals in Queensland.

Chapman SJ, McKavanagh D, Burge ME, McPherson I, Walpole E, Hollingworth SA.

Asia Pac J Clin Oncol. 2017 Oct;13(5):e253-e261. doi: 10.1111/ajco.12518. Epub 2016 Jul 20.

PMID:
27435535
38.

Associations of Guideline Recommended Medications for Acute Coronary Syndromes With Fall-Related Hospitalizations and Cardiovascular Events in Older Women With Ischemic Heart Disease.

Peeters G, Tett SE, Hollingworth SA, Gnjidic D, Hilmer SN, Dobson AJ, Hubbard RE.

J Gerontol A Biol Sci Med Sci. 2017 Feb;72(2):259-265. doi: 10.1093/gerona/glw111. Epub 2016 Jul 6.

PMID:
27384327
39.

A Review of Medication Use as an Indicator of Human Health Impact in Environmentally Stressed Areas.

Hollingworth SA, Kim DD, Jagals P.

Ann Glob Health. 2016 Jan-Feb;82(1):111-8. doi: 10.1016/j.aogh.2016.01.010. Review.

40.

'Repeat' prescriptions and antibiotic resistance: findings from Australian community pharmacy.

Fredericks I, Hollingworth S, Pudmenzky A, Rossato L, Kairuz T.

Int J Pharm Pract. 2017 Feb;25(1):50-58. doi: 10.1111/ijpp.12273. Epub 2016 Jun 13.

PMID:
27293019
41.

Understanding quality use of medicines in refugee communities in Australian primary care: a qualitative study.

Kay M, Wijayanayaka S, Cook H, Hollingworth S.

Br J Gen Pract. 2016 Jun;66(647):e397-409. doi: 10.3399/bjgp16X685249. Epub 2016 May 9.

42.

Prescribing patterns of dental practitioners in Australia from 2001 to 2012. Antimicrobials.

Ford PJ, Saladine C, Zhang K, Hollingworth SA.

Aust Dent J. 2017 Mar;62(1):52-57. doi: 10.1111/adj.12427. Epub 2016 Dec 23.

43.

Glucagon-like peptide-1 agonists combating clozapine-associated obesity and diabetes.

Mayfield K, Siskind D, Winckel K, Russell AW, Kisely S, Smith G, Hollingworth S.

J Psychopharmacol. 2016 Mar;30(3):227-36. doi: 10.1177/0269881115625496. Epub 2016 Jan 22. Review.

PMID:
26801056
44.

Pharmacy workforce to prevent and manage non-communicable diseases in developing nations: The case of Nepal.

Khanal S, Nissen L, Veerman L, Hollingworth S.

Res Social Adm Pharm. 2016 Jul-Aug;12(4):655-9. doi: 10.1016/j.sapharm.2015.09.005. Epub 2015 Sep 28.

PMID:
26481826
45.

Weak Satiety Responsiveness Is a Reliable Trait Associated with Hedonic Risk Factors for Overeating among Women.

Dalton M, Hollingworth S, Blundell J, Finlayson G.

Nutrients. 2015 Sep 4;7(9):7421-36. doi: 10.3390/nu7095345.

46.

Consumer knowledge and perceptions about antibiotics and upper respiratory tract infections in a community pharmacy.

Fredericks I, Hollingworth S, Pudmenzky A, Rossato L, Syed S, Kairuz T.

Int J Clin Pharm. 2015 Dec;37(6):1213-21. doi: 10.1007/s11096-015-0188-y. Epub 2015 Sep 21.

PMID:
26391787
47.

Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial.

Mayfield K, Siskind D, Winckel K, Hollingworth S, Kisely S, Russell AW.

BJPsych Open. 2015 Aug 20;1(1):67-73. eCollection 2015 Jun. Erratum in: BJPsych Open. 2016 Apr 13;2(2):187.

48.

Shift in disease burden from communicable to non-communicable diseases: aiming to achieve Universal Health Coverage in Nepal.

Khanal S, Veerman L, Hollingworth S, Nissen L.

Perspect Public Health. 2015 Jul;135(4):177-8. doi: 10.1177/1757913915586654. No abstract available.

PMID:
26148895
49.

Clozapine in the community: Improved access or risky free-for-all?

Winckel K, Siskind D, Hollingworth S, Robinson G, Mitchell S, Varghese D, Smith L, Wheeler AJ.

Aust N Z J Psychiatry. 2015 Oct;49(10):863-5. doi: 10.1177/0004867415592957. Epub 2015 Jun 22. No abstract available.

PMID:
26101397
50.

Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013.

Forrester T, Siskind D, Winckel K, Wheeler A, Hollingworth S.

Pharmacopsychiatry. 2015 Jul;48(4-5):164-9. doi: 10.1055/s-0035-1554713. Epub 2015 Jun 19.

PMID:
26091280

Supplemental Content

Loading ...
Support Center